Trial Profile
A phase II study of neoadjuvant bevacizumab plus docetaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 19 Feb 2013 Planned end date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 06 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 02 Dec 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.